https://www.thebodypro.com/article/expanded-access-program-mk-0518-investigational-hiv-integrase-inh
Raltegravir (Isentress)

Expanded Access Program for MK-0518, an Investigational HIV Integrase Inhibitor, Established for Patients With Limited Available Treatment Options

Worldwide Access Program Will Be Conducted Along With Phase III Studies

    Merck & Co., Inc.